Tonix Pharmaceuticals announces a poster presentation at the American Chemistry Society, ACS, Spring 2024 Meeting, held March 17-21, 2024, in New Orleans, Louisiana. The poster presentation titled, Oxytocin Analogs with Enhanced Craniofacial Antinociceptive Effects in Low Magnesium Formulations, describes the discovery and characterization of novel oxytocin analogues that are candidate treatments for craniofacial pain, excessive eating, and endocrinological conditions including bone health in autism and insulin resistance. “Intranasal oxytocin has several potential therapeutic applications,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “Preclinical studies have shown that oxytocin, a hypothalamic peptide hormone, simultaneously reduces food intake and increases energy expenditure, leading to weight loss.1-3 Intranasal oxytocin is well-tolerated and in published studies of adults, results in reduced caloric intake, increased fat burning and improved insulin sensitivity.1-3”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TNXP:
- Tonix Pharma Readies for Tonmya™ U.S. Launch and Production
- Tonix selects two contract manufacturing organizations for launch of Tonmya
- Tonix Pharma Announces Full Integration and Future Plans
- Tonix announces transition to fully integrated biopharmaceutical company
- Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024